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Objective. Juvenile idiopathic arthritis (JIA) is a
chronic rheumatic disease of childhood. Two well-
established genetic factors known to contribute to JIA
susceptibility, HLA and PTPN22, account for less than
half of the genetic susceptibility to disease; therefore,
additional genetic factors have yet to be identified. The
purpose of this study was to perform a systematic search
of the genome to identify novel susceptibility loci for
JIA.
Methods. A genome-wide association study using
Affymetrix GeneChip 100K arrays was performed in a
discovery cohort (279 cases and 184 controls). Single-
nucleotide polymorphisms (SNPs) showing the most
significant differences between cases and controls were
then genotyped in a validation sample of cases (n 
321) and controls, combined with control data from the
1958 UK birth cohort (n  2,024). In one region in
which association was confirmed, fine-mapping was
performed (654 cases and 1,847 controls).
Results. Of the 112 SNPs that were significantly
associated with JIA in the discovery cohort, 6 SNPs were
associated with JIA in the independent validation co-
hort. The most strongly associated SNP mapped to the
HLA region, while the second strongest association was
with a SNP within the VTCN1 gene. Fine-mapping of
that gene was performed, and 10 SNPs were found to be
associated with JIA.
Conclusion. This study is the first to successfully
apply a SNP-based genome-wide association approach
to the investigation of JIA. The replicated association
with markers in the VTCN1 gene defined an additional
susceptibility locus for JIA and implicates a novel
pathway in the pathogenesis of this chronic disease of
childhood.
Juvenile idiopathic arthritis (JIA) is a generic
term for arthritis that persists for more than 6 weeks and
has an onset before the age of 16 years. It is the most
common chronic rheumatic disease of childhood, with a
prevalence of 1 in 1,000 persons. The clinical phenotype
of JIA is complex. In the current International League of
Associations for Rheumatology (ILAR) classification
system, the disease is divided into 7 clinical subgroups,
and outcome varies according to phenotype (1).
The cause of JIA is complex, involving both
genetic and environmental risk factors. To date, only 2
genetic risk factors, HLA and the PTPN22 gene, have
been unequivocally confirmed as JIA susceptibility
genes in multiple populations. Other genes, such as MIF,
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258IL6, IL10, and TNF, show some evidence of association
with JIA in different populations and subtypes (2).
However, it has been hypothesized that these genes
account for only a small proportion of the total genetic
contribution to disease, and there are likely to be other
susceptibility loci, the identification of which may lead
the way to a greater understanding of the pathways
involved in the disease pathogenesis and, ultimately, to
new therapies.
The recent trend for taking a “hypothesis-free”
approach with the use of genome-wide association stud-
ies has proved to be highly successful in identifying
genetic risk factors for other complex diseases, such as
rheumatoid arthritis and type 2 diabetes mellitus (3). We
therefore chose to adopt this strategy to identify novel
JIA susceptibility loci. We performed a multistage case–
control association study investigating 112,496 single-
nucleotide polymorphisms (SNPs) spanning the genome
in a discovery sample set of JIA cases and controls,
followed by validation of significantly associated poly-
morphisms in an independent sample set. Fine-mapping
of one of the replicated regions implicated the VTCN1
gene in JIA susceptibility.
PATIENTS AND METHODS
Study overview. A multistage case–control association
study was undertaken. In the first stage, genotype frequencies
in a subset of JIA cases were compared with those in popula-
tion controls (discovery cohort), using an Affymetrix Gene-
Chip 100K array (Affymetrix, Santa Clara, CA). SNPs showing
evidence of association in that dataset (P  0.001) were
genotyped in the remaining JIA cases (validation cases) and in
an independent cohort of population controls. Genotype fre-
quencies in a further control population were available from
public databases, and these data were combined with the data
from the latter group of controls (validation controls). Geno-
type frequencies were compared between the validation cases
and controls. For one region where association was confirmed
in this independent cohort, fine-mapping was performed to
refine the region of association.
Patients and controls. All patients with JIA fulfilled
the ILAR diagnostic criteria (1), had an age at JIA onset of
16 years, were white, and were recruited from across the UK
as part of the British Society for Paediatric and Adolescent
Rheumatology (BSPAR) National Repository for JIA.
Healthy control subjects were identified from blood donor
registries and general practitioner records, and samples were
obtained. All individuals were recruited with approval of the
local ethics committees (North-West Multi-Centre Research
Ethics Committee [MREC 99/8/84] and the University of
Manchester Committee on the Ethics of Research on Human
Beings) and provided informed consent. Genotype data were
available from public databases for additional population
samples recruited as part of the 1958 birth cohort. All controls
were white and were from the UK.
Discovery cohort. The 279 JIA cases in the discovery set
had a mean age at onset of 4.8 years, and 72% were female.
JIA subtypes were as follows: persistent oligoarthritis (n 
133), extended oligoarthritis (n  80), rheumatoid factor
(RF)–negative polyarthritis (n  57), and RF-positive polyar-
thritis (n  9). The controls consisted of 184 subjects with no
history of inflammatory arthritis; 48% of them were female.
Validation cohort. The 321 JIA cases in the validation
set had a mean age at onset of 6.3 years, and 79% were female.
JIA subtypes were as follows: persistent oligoarthritis (n  74),
extended oligoarthritis (n  67), RF-negative polyarthritis
(n  120), and RF-positive polyarthritis (n  60). Controls
comprised 544 individuals with no history of inflammatory
arthritis, as well as up to 1,480 individuals from the 1958 UK
birth cohort.
Fine-mapping cohort. The 654 JIA cases in the fine-
mapping cohort had a mean age at onset of 6.9 years, and 68%
were female. This cohort represents a combined set of all
ILAR JIA subgroups, as follows: persistent oligoarthritis (n 
194), extended oligoarthritis (n  86), RF-negative polyarthri-
tis (n  138), RF-positive polyarthritis (n  35), systemic JIA
(n  115), enthesitis-related JIA (n  28), psoriatic JIA (n 
51), and unclassified (n  7). Controls comprised 367 individ-
uals with no history of inflammatory arthritis, as well as up to
1,480 individuals from the 1958 UK birth cohort. This is not an
independent data set, and some of the cases and controls in
this set were included in the discovery and validation cohorts.
Genotyping. Discovery cohort. The samples in the
discovery cohort (n  463) were processed according to the
instructions provided in the Affymetrix GeneChip Human
Mapping 100K Assay Manual (online at http://www.affymetrix.
com). Samples with a 93% genotype call rate were dropped
from the analysis. SNPs that had a minor allele frequency of
5%, that failed to genotype in 5% of samples, or that had
a Hardy-Weinberg equilibrium P value of 0.0001 in controls
were excluded from the analysis.
Validation cohort. SNPs showing evidence of an asso-
ciation with JIA in the discovery cohort at P  0.001 were
selected for testing in the validation cohort. Samples were
genotyped using Sequenom MassArray genotyping technology
according to the manufacturer’s instructions (Sequenom, San
Diego, CA; online at http://www.sequenom.com).
Fine-mapping of associated regions. The genotype data
from the HapMap project (online at http://www.HapMap.org)
in the CEPH population (i.e., Utah residents with ancestry
from northern and western Europe; collected by the Centre
d’E ´tude du Polymorphisme Humain [CEPH]) were used to
determine pairwise tagging SNPs, using the Tagger software
(online at http://www.broad.mit.edu/tools/software.html).
The fine-mapping cohort was genotyped using Sequenom
MassArray genotyping technology, as in the validation cohort.
Statistical analysis. Genotype and allele frequencies
were compared between cases and controls using Stata version
9 SE (StataCorp, College Station, TX) and Plink (online at
http://pngu.mgh.harvard.edu/purcell/plink/) software. The
Armitage test for trend was used to test for association.
Stratification by ILAR subtype for associated VTCN1 SNPs
was also performed.
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Findings in the discovery set. A total of 112,496
SNPs were genotyped in the discovery sample. Since the
power calculations for the discovery set had been based
upon the detection of modest effect sizes for common
alleles, we excluded SNPs with a minor allele frequency
of 5% (n  21,707). A further 1,883 SNPs were ex-
cluded because of failure to genotype in 5% of sam-
ples, and 224 SNPs were excluded because of significant
deviation from Hardy-Weinberg equilibrium. A total of
88,682 autosomal SNPs were therefore analyzed for
association with JIA, and 84,235 of these SNPs (95%)
had 98% complete genotype data.
One hundred twelve autosomal SNPs were asso-
ciated with JIA at P  0.001, and these SNPs were
selected for genotyping in the validation cohort. (A table
of the 112 SNPs taken through for analysis in the
validation cohort is available upon request from the
corresponding author.) One SNP (rs2187684) was situ-
ated in the HLA region on chromosome 6p21. Two
SNPs that mapped to the PTPN22 region, which were
almost perfectly correlated with each other but which
showed only modest correlation with the known PTPN22
functional variant (rs2476601; r
2  0.27 for rs1217407
and R620W), were weakly associated with JIA (P 
0.015 for rs1217407 and P  0.014 for rs1217380).
Findings in the validation cohort. Of the 112
SNPs associated with JIA, 102 were successfully geno-
typed in the validation cohort (call rate 90%, Hardy-
Weinberg equilibrium at P  0.001). Of these 102 SNPs,
47 had been directly genotyped in the 1958 UK birth
cohort controls, whereas imputed data were available for
the remaining 55 SNPs (4). Of the 55 imputed SNPs, 48
had confidence scores exceeding 95% (Table 1).
Of the 102 SNPs tested, 11 were associated with
JIA at P  0.05, 6 of which showed association with the
same allele as at the discovery stage (Tables 1 and 2).
The most strongly associated SNP (rs2187684) mapped
to the HLA region (207 kb from the HLA–DRB1 locus
and 153 kb from the HLA–DQB1 locus), while the
Table 1. Single-nucleotide polymorphisms associated with juvenile idiopathic arthritis in the validation cohort*
Marker Chr. Position
HWE in
controls
MAF
Genotype frequency, no. (%)
Birth cohort
directly
genotyped
(CS)
P
for
trend
OR
(95% CI)
for allele
Cases
(n  321)
Controls
(n  2,024)
Cases
(n  321)
Controls
(n  2,024)
11 12 22 11 12 22
rs2187684 6 32872697 0.1 0.28 0.38 12
(6.6)
76
(41.7)
94
(51.6)
297
(15.5)
868
(45.4)
745
(39.0)
No (0.99) 0.00006 0.61 (0.48–
0.78)
rs2358820 1 117513434 0.65 0.04 0.08 0
(0)
14
(7.7)
168
(92.3)
14
(0.8)
283
(14.8)
1,612
(84.4)
No (0.99) 0.003 0.45 (0.26–
0.78)
rs939898 12 90191601 0.52 0.17 0.21 5
(2.0)
74
(28.9)
177
(69.1)
73
(4.1)
594
(33.8)
1,092
(62.1)
No (0.99) 0.01 0.74 (0.57–
0.94)
rs9311745 3 59976865 1 0.05 0.03 1
(0.4)
23
(8.9)
233
(90.7)
1
(0.1)
102
(5.8)
1,655
(94.1)
No (0.97) 0.02 1.68 (1.07–
2.62)
rs2833547 21 32171851 0.91 0.23 0.28 12
(6.6)
60
(33.2)
109
(60.2)
148
(8.0)
743
(40.4)
948
(51.6)
Yes (NA) 0.04 0.77 (0.59–
0.99)
rs1074044 13 87841327 0.21 0.53 0.48 44
(24.9)
99
(55.9)
34
(19.2)
430
(23.2)
895
(48.4)
525
(28.4)
Yes (NA) 0.05 1.24 (1.0–
1.54)
* Chr.  chromosome; HWE  Hardy-Weinberg equilibrium; MAF  minor allele frequency; CS  confidence score; OR  odds ratio; 95% CI 
95% confidence interval; NA  not applicable.
Table 2. Comparison of single-nucleotide polymorphisms found to be associated with juvenile idiopathic arthritis in the discovery and validation
stages*
Marker Chr.
Discovery stage Validation stage
HWE in
controls
MAF
P
for
trend
OR
(95% CI)
for allele
HWE in
controls
MAF
P
for
trend
OR
(95% CI)
for allele
Cases
(n  279)
Controls
(n  184)
Cases
(n  321)
Controls
(n  2,024)
rs2187684 6 0.09 0.28 0.38 0.0008 0.62 (0.47–0.82) 0.1 0.28 0.38 0.00006 0.61 (0.48–0.78)
rs2358820 1 0.22 0.04 0.1 0.0004 0.4 (0.23–0.68) 0.65 0.04 0.08 0.003 0.45 (0.26–0.78)
rs939898 12 0.05 0.16 0.25 0.0004 0.56 (0.40–0.78) 0.52 0.17 0.21 0.01 0.74 (0.57–0.94)
rs9311745 3 1 0.08 0.02 0.0001 3.67 (1.79–7.5) 1 0.05 0.03 0.02 1.68 (1.07–2.62)
rs2833547 21 0.62 0.22 0.33 0.0006 0.6 (0.44–0.8) 0.91 0.23 0.28 0.04 0.77 (0.59–0.99)
rs1074044 13 0.09 0.56 0.43 0.0001 1.67 (1.27–2.19) 0.21 0.53 0.48 0.05 1.24 (1.0–1.54)
* Chr.  chromosome; HWE  Hardy-Weinberg equilibrium; MAF  minor allele frequency; OR  odds ratio; 95% CI  95% confidence interval.
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NOVEL SUSCEPTIBILITY LOCUS FOR JIA 261second strongest association was with a SNP that
mapped to the VTCN1 gene, rs2358820. The VTCN1
gene was therefore investigated further.
Results of fine-mapping of the VTCN1 gene.
According to the HapMap data, 70 SNPs mapped to the
VTCN1 gene, but only 27 were required to tag the region
in order to provide 100% coverage of all nongenotyped
SNPs at an r
2 level of 0.8. Of these 27 SNPs selected
for genotyping, assays could not be designed for 2. The
25 remaining SNPs captured 96% of the known varia-
tion across the gene. For these 25 SNPs, 7 had been
genotyped directly in the 1958 UK birth cohort con-
trols, whereas imputed data were available for the
remaining 18 SNPs (4). Of the 18 imputed SNPs, 8 had
a confidence score of 95% (Table 3). Ten SNPs
mapping to the VTCN1 gene showed a nominal associ-
ation with JIA at P  0.05. Seven of them (rs12046117,
rs10923223, rs7415876, rs12038533, rs6669320, rs10923217,
and rs4376721) lay within intron 1, rs2051047 lay within
intron 3, rs2358817 lay within intron 4, and rs6673837 lay
in the 3 region of the gene (Table 3).
There was only moderate linkage disequilibrium
across the gene as a whole, but the associated SNPs
appeared to map to 3 regions within the gene. The SNPs
showing the strongest association (rs10923223 and
rs12046117) are situated in intron 1 and demonstrated
moderate linkage disequilibrium with each other (r
2 
0.68). However, this finding should be viewed with
caution, since the confidence score for the imputed
genotypes in the control population was 95%, suggest-
ing that this may have introduced some bias.
A second group of SNPs in intron 1 showed
modest evidence of association, in which the major allele
was associated with disease. SNPs rs2358817 and
rs2051047 showed stronger evidence of association and
mapped to introns 3 and 4, respectively. They demon-
strated a strong correlation with each other and probably
represent a single effect (r
2  0.83).
This analysis was performed in all JIA subtypes.
Reanalysis using only the JIA subtypes included in the
original discovery stage did not alter the results. Com-
parison of genotype counts for VTCN1 SNPs across the
different ILAR subtypes showed no significant differ-
ences. (A table showing the ILAR stratification analysis
of VTCN1-associated SNPs is available upon request
from the corresponding author.)
DISCUSSION
In this study, we used a whole-genome associa-
tion approach to identify novel JIA susceptibility loci,
and for one of these regions, we performed fine-
mapping analysis to refine the extent of association. We
identified associations between JIA and polymorphisms
mapping to the VTCN1 gene.
The possibility that this finding could represent a
false-positive result requires consideration. This could
arise as a result of population stratification. However,
the Wellcome Trust Case Control Consortium study
previously established that there was very little evidence
of this across the UK (3). They found only 13 loci ex-
hibiting significant geographic variation, none of which
overlapped with loci in the present investigation.
We used a modest threshold for significance (P 
0.001), accepting that the majority of SNPs showing
association would be false-positives and would therefore
fail to be replicated in independent cohorts. We per-
formed no corrections for multiple testing, but instead,
took the approach of validation of any significant results
in independent cohorts. Using this approach, strong
evidence for an association with HLA was detected,
serving as a proof-of-concept that established JIA sus-
ceptibility factors could be identified.
In contrast, SNPs mapping to the other con-
firmed JIA susceptibility locus, the PTPN22 gene,
showed only weak associations. This is likely due to the
low correlation between SNPs on the Affymetrix Gene-
Chip 100K array and the known PTPN22 causal variant,
rs2476601 (r
2  0.27). Furthermore, the Affymetrix
100K GeneChip Array is only estimated to capture 35%
of known variation across the genome, and it is therefore
likely that a number of JIA susceptibility loci remain to
be identified. Nonetheless, there have been notable
successes in identifying genes that underlie complex
diseases using a staged approach in modest sample sizes
and with the same SNP density as in this study. Exam-
ples include the complement factor H gene, which has
been widely confirmed as a susceptibility gene for age-
related macular degeneration (5), and a region on
chromosome 6q23 (6), which has been confirmed as a
rheumatoid arthritis susceptibility locus (7).
It is likely that other JIA-associated genes are
present but were not identified in our study because the
small sample size used in the discovery set limited the
power to detect causal variants with small effect sizes
(false-negative); nonetheless, this is the most compre-
hensive genome-wide association study of JIA to date.
The sample size used in the discovery cohort was
selected based on its power to detect effect sizes equiv-
alent to the confirmed JIA susceptibility causal variant
within the PTPN22 gene, but we attempted to increase
the power by selecting more homogeneous JIA cases,
262 HINKS ET ALexcluding systemic-onset JIA, psoriatic JIA, and enthesitis-
related JIA cases. However, the male to female ratio
between the case and control groups was not matched in
this study, and as such, the observed data are not a true
representation of all genetic association.
Despite these limitations, association of the
VTCN1 gene with JIA was detected and replicated. The
gene is an interesting candidate for this autoimmune
disease, since it is part of a recently identified inhibitory
pathway that is important in the prevention of detrimen-
tal inflammatory responses, such as the autoimmune
response seen in the joints of children with JIA. VTCN1,
which is also known as B7-H4, is expressed on activated
T cells, B cells, monocytes, and dendritic cells (8), and
evidence suggests that it plays a role in the negative
regulation of T cell responses. It is a member of the B7
family of costimulatory molecules, and it has been
proposed that the ligand for VTCN1 is the B and T
lymphocyte attenuator, an inhibitory receptor on T cells.
Therefore, it may be involved in the attenuation of
inflammatory responses in peripheral tissue (8). All 10
associated variants are intronic, and none has a recog-
nized function as yet. Resequencing and further geno-
typing in the region will be required to identify the
causal variants before functional studies can be under-
taken to determine how they predispose to disease.
In summary, we identified 6 regions where there
is replicated evidence of association with susceptibility
to JIA, including the VTCN1 gene. Although confirma-
tion of this association in different populations will be
important, the identification of VTCN1 as a JIA suscep-
tibility locus represents a novel pathway by which to
explore more about the cause of the disease. In turn, this
may lead to novel therapies for this disabling, chronic
arthritis of childhood.
AUTHOR CONTRIBUTIONS
Dr. Hinks had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy of the
data analysis.
Study design. Hinks, Barton, Kennedy, John, Worthington, Thomson.
Acquisition of data. Hinks, Eyre, Bowes, Cargill, Wang, Kennedy,
Thomson.
Analysis and interpretation of data. Hinks, Barton, Shephard, Eyre,
Cargill, Wang, Kennedy, John, Worthington, Thomson.
Manuscript preparation. Hinks, Barton, Ke, Kennedy, John,
Thomson.
Statistical analysis. Hinks, Shephard, Cargill, Ke, John.
REFERENCES
1. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners
P, et al. Revision of the proposed classification criteria for juvenile
idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991–4.
2. Thomson W, Donn R. Juvenile idiopathic arthritis genetics—what’s
new? What’s next? [review]. Arthritis Res 2002;4:302–6.
3. Wellcome Trust Case Control Consortium. Genome-wide associa-
tion study of 14,000 cases of seven common diseases and 3,000
shared controls. Nature 2007;447:661–78.
4. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new
multipoint method for genome-wide association studies by imputa-
tion of genotypes. Nat Genet 2007;39:906–13.
5. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al.
Complement factor H polymorphism in age-related macular degen-
eration. Science 2005;308:385–9.
6. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, et al.
Investigation of putative rheumatoid arthritis susceptibility loci
identified in the WTCCC study confirms association to a novel
locus at 6q23. Nat Genet 2008;39:1431–3.
7. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller
J, et al. Two independent alleles at 6q23 associated with risk of
rheumatoid arthritis. Nat Genet 2007;39:1477–82.
8. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al.
B7-H4, a molecule of the B7 family, negatively regulates T cell
immunity. Immunity 2003;18:849–61.
NOVEL SUSCEPTIBILITY LOCUS FOR JIA 263